Your browser doesn't support javascript.
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak.
Tagliamento, Marco; Spagnolo, Francesco; Poggio, Francesca; Soldato, Davide; Conte, Benedetta; Ruelle, Tommaso; Barisione, Emanuela; De Maria, Andrea; Del Mastro, Lucia; Di Maio, Massimo; Lambertini, Matteo.
  • Tagliamento M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • Spagnolo F; Department of Medical Oncology, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Poggio F; Department of Medical Oncology, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Soldato D; Department of Medical Oncology, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Conte B; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • Ruelle T; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Barisione E; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • De Maria A; Department of Medical Oncology, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Del Mastro L; Department of Medical Oncology, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Di Maio M; Interventional Pneumology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Lambertini M; Department of Health Sciences, University of Genova, Genova, Italy.
Eur J Clin Invest ; 50(9): e13315, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-597270
Semantic information from SemMedBD (by NLM)
1. Immune Checkpoint Inhibitor ASSOCIATED_WITH Neoplasms
Subject
Immune Checkpoint Inhibitor
Predicate
ASSOCIATED_WITH
Object
Neoplasms
2. Syndrome PROCESS_OF Patients
Subject
Syndrome
Predicate
PROCESS_OF
Object
Patients
3. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
4. Perception PROCESS_OF Cancer Patient
Subject
Perception
Predicate
PROCESS_OF
Object
Cancer Patient
5. Steroids TREATS Toxic effect
Subject
Steroids
Predicate
TREATS
Object
Toxic effect
6. Immune Checkpoint Inhibitor ASSOCIATED_WITH Neoplasms
Subject
Immune Checkpoint Inhibitor
Predicate
ASSOCIATED_WITH
Object
Neoplasms
7. Syndrome PROCESS_OF Patients
Subject
Syndrome
Predicate
PROCESS_OF
Object
Patients
8. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
9. Perception PROCESS_OF Cancer Patient
Subject
Perception
Predicate
PROCESS_OF
Object
Cancer Patient
10. Steroids TREATS Toxic effect
Subject
Steroids
Predicate
TREATS
Object
Toxic effect
ABSTRACT

BACKGROUND:

During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer have been reported to experience a more severe COVID-19 syndrome; moreover, there are concerns of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. MATERIALS AND

METHODS:

Between 6 and 16 May 2020, a 22-item survey was sent to Italian physicians involved in administering ICIs. It aimed at exploring the perception about SARS-CoV-2-related risks in cancer patients receiving ICIs, and the attitudes towards their management.

RESULTS:

The 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS-CoV-2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labelled dose of each ICI and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS-CoV-2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnoea and cough as infected by SARS-CoV-2 until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune-related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned.

CONCLUSIONS:

These results highlight the uncertainties around the perception of a potential interference between ICIs and COVID-19, supporting the need of focused studies on this topic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Disease Outbreaks / Coronavirus Infections / Immunologic Factors / Neoplasms Type of study: Controlled clinical trial / Diagnostic study / Etiology study / Randomized controlled trials / Risk factors Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Eur J Clin Invest Year: 2020 Document Type: Article Affiliation country: Eci.13315

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Disease Outbreaks / Coronavirus Infections / Immunologic Factors / Neoplasms Type of study: Controlled clinical trial / Diagnostic study / Etiology study / Randomized controlled trials / Risk factors Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Eur J Clin Invest Year: 2020 Document Type: Article Affiliation country: Eci.13315